|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shang N, Wang H, Bank T, Perera A, Joyce
C, Kuffel G, Zilliox MJ, Cotler SJ, Ding X, Dhanarajan A, et al:
Focal adhesion kinase and β-catenin cooperate to induce
hepatocellular carcinoma. Hepatology. 70:1631–1645. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Massafra V, Pellicciari R, Gioiello A and
van Mil SW: Progress and challenges of selective farnesoid X
receptor modulation. Pharmacol Ther. 191:162–177. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tran M, Liu Y, Huang W and Wang L: Nuclear
receptors and liver disease: Summary of the 2017 basic research
symposium. Hepatol Commun. 2:765–777. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Huang XF, Zhao WY and Huang WD: FXR and
liver carcinogenesis. Acta Pharmacol Sin. 36:37–43. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jiang Y, Iakova P, Jin J, Sullivan E,
Sharin V, Hong IH, Anakk S, Mayor A, Darlington G, Finegold M, et
al: Farnesoid X receptor inhibits gankyrin in mouse livers and
prevents development of liver cancer. Hepatology. 57:1098–1106.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Su H, Ma C, Liu J, Li N, Gao M, Huang A,
Wang X, Huang W and Huang X: Downregulation of nuclear receptor FXR
is associated with multiple malignant clinicopathological
characteristics in human hepatocellular carcinoma. Am J Physiol
Gastrointest Liver Physiol. 303:G1245–1253. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu N, Meng Z, Lou G, Zhou W, Wang X,
Zhang Y, Zhang L, Liu X, Yen Y, Lai L, et al: Hepatocarcinogenesis
in FXR−/− mice mimics human HCC progression that
operates through HNF1alpha regulation of FXR expression. Mol
Endocrinol. 26:775–785. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Huang X, Zeng Y, Wang X, Ma X, Li Q, Li N,
Su H and Huang W: FXR blocks the growth of liver cancer cells
through inhibiting mTOR-s6K pathway. Biochem Biophys Res Commun.
474:351–356. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Aravalli RN, Steer CJ and Cressman EN:
Molecular mechanisms of hepatocellular carcinoma. Hepatology.
48:2047–2063. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen J, Rajasekaran M, Xia H, Zhang X,
Kong SN, Sekar K, Seshachalam VP, Deivasigamani A, Goh BK, Ooi LL,
et al: The microtubule-associated protein PRC1 promotes early
recurrence of hepatocellular carcinoma in association with the
Wnt/β-catenin signalling pathway. Gut. 65:1522–1534. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dong LW, Yang GZ, Pan YF, Chen Y, Tan YX,
Dai RY, Ren YB, Fu J and Wang HY: The oncoprotein p28GANK
establishes a positive feedback loop in β-catenin signaling. Cell
Res. 21:1248–1261. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fu Y, Zheng S, An N, Athanasopoulos T,
Popplewell L, Liang A, Li K, Hu C and Zhu Y: β-catenin as a
potential key target for tumor suppression. Int J Cancer.
129:1541–1551. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schmalhofer O, Brabletz S and Brabletz T:
E-cadherin, beta-catenin, and ZEB1 in malignant progression of
cancer. Cancer Metastasis Rev. 28:151–166. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wolfe A, Thomas A, Edwards G, Jaseja R,
Guo GL and Apte U: Increased activation of the Wnt/β-catenin
pathway in spontaneous hepatocellular carcinoma observed in
farnesoid X receptor knockout mice. J Pharmacol Exp Ther.
338:12–21. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Meng Z, Fu X, Chen X, Zeng S, Tian Y, Jove
R, Xu R and Huang W: miR-194 is a marker of hepatic epithelial
cells and suppresses metastasis of liver cancer cells in mice.
Hepatology. 52:2148–2157. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
National Research Council (US) Committee
for the Update of the Guide for the Care and Use of Laboratory
Animals, . The National Academies Collection: Reports Funded by
National Institutes of Health: Guide for the Care and Use of
Laboratory Animals. 8th. National Academies Press; Washington, DC:
2011
|
|
19
|
Eun JR, Jung YJ, Zhang Y, Zhang Y,
Tschudy-Seney B, Ramsamooj R, Wan YJ, Theise ND, Zern MA and Duan
Y: Hepatoma SK Hep-1 cells exhibit characteristics of oncogenic
mesenchymal stem cells with highly metastatic capacity. PLoS One.
9:e1107442014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Heffelfinger SC, Hawkins HH, Barrish J,
Taylor L and Darlington GJ: SK HEP-1: A human cell line of
endothelial origin. In Vitro Cell Dev Biol. 28A:136–142. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shang X, Lin X, Alvarez E, Manorek G and
Howell SB: Tight junction proteins claudin-3 and claudin-4 control
tumor growth and metastases. Neoplasia. 14:974–985. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Perugorria MJ, Olaizola P, Labiano I,
Esparza-Baquer A, Marzioni M, Marin JJG, Bujanda L and Banales JM:
Wnt-β-catenin signalling in liver development, health and disease.
Nat Rev Gastroenterol Hepatol. 16:121–136. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kawano Y and Kypta R: Secreted antagonists
of the Wnt signalling pathway. J Cell Sci. 116:2627–2634. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jiang X, Charlat O, Zamponi R, Yang Y and
Cong F: Dishevelled promotes Wnt receptor degradation through
recruitment of ZNRF3/RNF43 E3 ubiquitin ligases. Mol Cell.
58:522–533. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Clevers H and Nusse R: Wnt/β-catenin
signaling and disease. Cell. 149:1192–1205. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Koutsounas I, Giaginis C and Theocharis S:
Farnesoid X receptor (FXR) from normal to malignant state. Histol
Histopathol. 27:835–853. 2012.PubMed/NCBI
|
|
27
|
Makishima M, Okamoto AY, Repa JJ, Tu H,
Learned RM, Luk A, Hull MV, Lustig KD, Mangelsdorf DJ and Shan B:
Identification of a nuclear receptor for bile acids. Science.
284:1362–1365. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yang F, Huang X, Yi T, Yen Y, Moore DD and
Huang W: Spontaneous development of liver tumors in the absence of
the bile acid receptor farnesoid X receptor. Cancer Res.
67:863–867. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Khanna C and Hunter K: Modeling metastasis
in vivo. Carcinogenesis. 26:513–523. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liang Y, Feng Y, Zong M, Wei XF, Lee J,
Feng Y, Li H, Yang GS, Wu ZJ, Fu XD and Feng GS: β-catenin
deficiency in hepatocytes aggravates hepatocarcinogenesis driven by
oncogenic β-catenin and MET. Hepatology. 67:1807–1822. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Macdonald BT, Semenov MV and He X:
SnapShot: Wnt/beta-catenin signaling. Cell. 131:12042007.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gonzalez DM and Medici D: Signaling
mechanisms of the epithelial-mesenchymal transition. Sci Signal.
7:re82014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yu W, Li L, Zheng F, Yang W, Zhao S, Tian
C, Yin W, Chen Y, Guo W, Zou L and Deng W: β-catenin cooperates
with CREB binding protein to promote the growth of tumor cells.
Cell Physiol Biochem. 44:467–478. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fabregat I, Moreno-Càceres J, Sánchez A,
Dooley S, Dewidar B, Giannelli G and Ten Dijke P: TGF-β signalling
and liver disease. FEBS J. 283:2219–2232. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fabregat I and Caballero-Díaz D:
Transforming growth factor-β-induced cell plasticity in liver
fibrosis and hepatocarcinogenesis. Front Oncol. 8:3572018.
View Article : Google Scholar : PubMed/NCBI
|
